TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 43nMAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 310nMAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 410nMAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 560nMAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 650nMAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 1.10E+3nMpH: 7.2 T: 2°CAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 1.20E+3nMpH: 7.2 T: 2°CAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 1.20E+3nMpH: 7.2 T: 2°CAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 1.40E+3nMAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 1.50E+3nMAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 2.50E+3nMAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 2.90E+3nMpH: 7.2 T: 2°CAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 3.00E+3nMpH: 7.2 T: 2°CAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 3.50E+3nMpH: 7.2 T: 2°CAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 3.80E+3nMAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 4.00E+3nMpH: 7.2 T: 2°CAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 4.70E+3nMpH: 7.2 T: 2°CAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 4.90E+3nMpH: 7.2 T: 2°CAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 5.50E+3nMAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 7.40E+3nMpH: 7.2 T: 2°CAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 9.80E+3nMpH: 7.2 T: 2°CAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 9.80E+3nMpH: 7.2 T: 2°CAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 1.00E+4nMAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 1.00E+4nMAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 1.10E+4nMAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 1.20E+4nMpH: 7.2 T: 2°CAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 1.30E+4nMAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 1.40E+4nMpH: 7.2 T: 2°CAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 1.40E+4nMpH: 7.2 T: 2°CAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 1.60E+4nMpH: 7.2 T: 2°CAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 1.60E+4nMpH: 7.2 T: 2°CAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 1.60E+4nMpH: 7.2 T: 2°CAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 1.80E+4nMpH: 7.2 T: 2°CAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 1.80E+4nMAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 1.80E+4nMpH: 7.2 T: 2°CAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 1.90E+4nMpH: 7.2 T: 2°CAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 1.90E+4nMAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 2.20E+4nMpH: 7.2 T: 2°CAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 2.20E+4nMAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 2.60E+4nMpH: 7.2 T: 2°CAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 2.60E+4nMpH: 7.2 T: 2°CAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 2.60E+4nMAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 2.90E+4nMAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 2.90E+4nMAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 3.10E+4nMpH: 7.2 T: 2°CAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 3.40E+4nMAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 3.60E+4nMAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 4.40E+4nMAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 4.50E+4nMpH: 7.2 T: 2°CAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase B-raf [V600E](Homo sapiens (Human))
Cancer Research Uk Centre For Cancer Therapeutics
Cancer Research Uk Centre For Cancer Therapeutics
Affinity DataIC50: 4.50E+4nMAssay Description:BRAF kinase activity was quantified using a DELFIA-based MEK1 phosphorylation assay. IC50 values were derived from the sigmoidal dose-response curves...More data for this Ligand-Target Pair